immunotherapy, as surrogates for OS鈥攑rogression-free survival (PFS) status at 24months (PFS24) and complete response at 30months (CR30) post-ASCT. ... A Jiménez-Ubieto,C Grande,D Caballero,... - 《Cancer Medicine》 被引量: 0发表: 2017年 High-dose therapy and autologous stem-cell ...